Compare Super Micro Computer Inc (SMCI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs Viatris Inc — how do they compare? Super Micro Computer Inc trades at $29.88 (market cap $15.41B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.83% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals.
| SMCI | VTRS | |
|---|---|---|
Market Cap | $15.41B | $19.79B |
Sector | Technology | Health |
52-Week High | $60.71 | $17.39 |
52-Week Low | $20.53 | $8.74 |
Enterprise Value | $22.93B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $23.83, down 1.41% on the day, with technical indicators showing bearish momentum despite recent positive earnings beats. The company reported strong Q1 2026 results with EPS of $0.84 beating expectations of $0.617, while preliminary Q4 guidance indicates significant margin expansion to 15-17% and over $60 billion in new orders. Valuation metrics remain attractive with P/E of 12.54 and P/S of 0.47, though cash flow trends show volatility with 2026 projections indicating operational challenges.
The outlook appears cautiously optimistic with analyst consensus price target of $36.71 representing 54% upside potential, though technical weakness and competitive pressures in AI hardware create near-term headwinds. Key risks include execution on massive order backlog, margin sustainability, and intense competition from Dell and HPE in the AI server market.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
